Information Provided By: 
Fly News Breaks for June 3, 2016
JAZZ
Jun 3, 2016 | 06:52 EDT
Following the acquisition of Celator Pharmaceuticals and specifically Vyxeos, Piper Jaffray analyst David Amsellem believes Jazz Pharmaceuticals is well positioned for multiple expansion. Peak U.S. Vyxeos sales of $300M-$400M are realistic, Amsellem tells investors in a research note. The analyst raised his price target for Jazz to $188 from $186 and reiterates an Overweight rating on the shares. The stock closed yesterday up $1.27 to $155.99.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
